Metabolic Complications of HIV and Antiretroviral Therapy: Dyslipidemia, Insulin Resistance, and Cardiovascular Disease
Summary
- Clinical trials have demonstrated improvement of dyslipidemia in patients who switched from abacavir/lamivudine to emtricitabine/tenofovir DF in combination with either efavirenz or a boosted PI[Moyle 2015; Behrens 2012; Campo 2013]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content